Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1340-1346

  Edick, Mathew J ^a   Gajjar, Amar ^a   Mahmoud, Hazem H ^a   Van de Poll, Matthijs E C ^a   Harrison, Patricia L ^a   Panetta, John C ^a   Rivera, Gaston K ^a   Ribeiro, Raul C ^a   Sandlund, John T ^a   Boyett, James M ^a   Pui, Ching Hon ^a   Relling, Mary V ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; ETOPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; FEMALE; INFANT; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; REMISSION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; ETOPOSIDE; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; REMISSION INDUCTION; VINCRISTINE;

EID: 0038175325     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.083     Document Type: Article

References (42)

1. Rivera GK, Hudson MM, Liu Q, et al: Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 88:831-837, 1996
2. Gaynon PS, Qu RP, Chappell RJ, et al: Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse-the Children's Cancer Group Experience. Cancer 82:1387-1395, 1998
3. Sadowitz PD, Smith SD, Shuster J, et al: Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 81:602-609, 1993
4. Beyermann B, Agthe AG, Adams HP, et al: Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. Blood 87:1532-1538, 1996
5. Ribeiro RC, Rivera GK, Hudson M, et al: An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 13:333-338, 1995
6. Crooks GM, Sato JK: Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 17:34-38, 1995
7. Belasco JB, Goldwein JW, Simms S, et al: Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children. Med Pediatr Oncol 34:125-131, 2000
8. Leahey AM, Bunin NJ, Belasco JB, et al: Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. Med Pediatr Oncol 34:313-318, 2000
9. Bernstein ML, Abshire TC, Pollock BH, et al: Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 19:68-72, 1997
10. Abromowitch M, Bowman WP, Ochs J, et al: Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia. J Clin Oncol 3:789-792, 1985
11. Davidson A, Gowing R, Lowis S, et al: Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 33: 1816-1822, 1997
12. Sonnichsen DS, Ribeiro RC, Luo X, et al: Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin Pharmacol Ther 58:99-107, 1995
13. Wolff JE, Molenkamp G, Westphal S, et al: Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer 89: 2131-2137, 2000
14. Kushner BH, Kramer K, Cheung NK: Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 17:3221-3225, 1999
15. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
16. Minami H, Ando Y, Sakai S, et al: Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 13:191-199, 1995
17. Bailey-Wood R, Dallimore CM, Littlewood TJ, et al: The effect of etoposide on human CFU-GM. Br J Cancer 52:613-617, 1985
18. D'Incalci M, Erba E, Vaghi M, et al: In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma. Eur J Cancer Clin Oncol 18:377-380, 1982
19. Harvey VJ, Slevin ML, Joel SP, et al: The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 16:178-181, 1986
20. Slevin ML, Joel SP, Whomsley R, et al: The effect of dose on the bioavailability of oral etoposide: Confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24:329-331, 1989
21. Hande KR, Krozely MG, Greco FA, et al: Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374-377, 1993
22. Mathew P, Ribeiro RC, Sonnichsen D, et al: Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 12:1452-1457, 1994
23. Bremnes RM, Sundstrom S, Vilsvik J, et al: Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 19:3532-3538, 2001
24. Glisson B, Scott C, Komaki R, et al: Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of Radiation Therapy Oncology Group Trial 93-12. J Clin Oncol 18:2990-2995, 2000
25. Mok TS, Zee B, Chan AT, et al: A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 89:543-550, 2000
26. Mahmoud HH, Rivera GK, Hancock ML, et al: Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 329:314-319, 1993
27. Gajjar A, Harrison PL, Sandlund JT, et al: Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96:3381-3384, 2000
28. McLeod HL, Relling MV: Stability of etoposide solution for oral use. Am J Hosp Pharm 49:2784-2785, 1992
29. Cai X, Woo MH, Edick MJ, et al: Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B A Biomed Sci Appl 728:241-250, 1999
30. Steimer JL, Mallet A, Golmard JL, et al: Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed-effect model. Drug Metab Rev 15:265-292, 1984
31. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134, 1979
32. Pinkerton CR, Dick G, Aherne GW: 24-hour plasma etoposide profile after oral and intravenous administration in children. Eur J Cancer 29A: 1479-1481, 1993
33. Chen CL, Rawwas J, Sorrell A, et al: Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. Leuk Lymphoma 42:317-327, 2001
34. van der Gaast A, Vlastuin M, Kok TC, et al: What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 × 100 mg, 2 × 50 mg, and 4 × 25 mg of oral etoposide daily for 21 days. Semin Oncol 19:8-12, 1992
35. Desoize B, Marechal F, Cattan A: Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. Br J Cancer 62:840-841, 1990
36. Kunitoh H, Watanabe K: Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 12:83-89, 1994
37. Evans WE, Sinkule JA, Crom WR, et al: Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 7:147-150, 1982
38. Rodman JH, Murry DJ, Madden T, et al: Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 12:2390-2397, 1994
39. Relling MV, McLeod HL, Bowman LC, et al: Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 56:503-511, 1994
40. Relling MV, Nemec J, Schuetz EG, et al: O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352-358, 1994
41. Gentile DM, Tomlinson ES, Maggs JL, et al: Dexamethasone metabolism by human liver in vitro: Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277:105-112, 1996
42. Relling MV, Crom WR, Pieper JA, et al: Hepatic drug clearance in children with leukemia: Changes in clearance of model substrates during remission-induction therapy. Clin Pharmacol Ther 41:651-660, 1987